In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Orphan Medical licenses Xyrem rights to Celltech

Executive Summary

Orphan Medical (drugs for rare diseases) has licensed Celltech Pharmaceuticals European marketing rights to Xyrem (sodium oxybate), a treatment for cataplexy associated with narcolepsy. The deal will last 10 years from European approval and will be automatically extended if the licensee wishes.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Intra-Biotech Deal
    • Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register